Gold prices bounce off 3-week lows; demand likely longer term
SAN DIEGO/CALGARY - Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), a biotechnology company with a market capitalization of $28.55 billion, announced Tuesday that its immunotherapy treatment pelareorep demonstrated significant survival benefits in pancreatic cancer and breast cancer patients compared to standard treatments. According to InvestingPro data, the company’s stock is currently trading near its Fair Value, reflecting market confidence in its clinical developments.
The clinical-stage biotechnology company reported two-year survival rates of 21.9% for metastatic pancreatic ductal adenocarcinoma (mPDAC) patients receiving pelareorep, compared to a 9.2% historical benchmark. Additionally, the company cited a 62% objective response rate when pelareorep was combined with chemotherapy and a checkpoint inhibitor.
In HR+/HER2- metastatic breast cancer studies, the company reported that pelareorep showed median overall survival benefits exceeding 10 months compared to standard chemotherapy treatments. The BRACELET-1 study showed median progression-free survival of 12.1 months for patients receiving pelareorep with paclitaxel versus 6.4 months for those receiving paclitaxel alone.
"We have meaningful clinical data in hand—not just signals," said Jared Kelly, Chief Executive Officer of Oncolytics, in the press release. "The survival benefit across multiple tumor types demands a focused approach to take pelareorep directly into registration-enabling trials." The company’s strong clinical progress is reflected in its financial performance, with revenue growth of 51.16% in the last twelve months. InvestingPro analysis shows analysts are predominantly bullish on the stock, with additional ProTips available to subscribers highlighting the company’s growth potential.
The company indicated it plans to leverage its FDA Fast Track designations, received in 2017 for metastatic breast cancer and in 2022 for pancreatic cancer, to advance toward registration-enabling studies.
According to the company, data from over 1,100 patients across multiple tumor types shows pelareorep has a favorable safety profile, with most common treatment-related adverse events being "flu-like" symptoms that are typically transient and manageable with over-the-counter medications. While currently operating at a loss, InvestingPro data indicates analysts expect the company to achieve profitability this year, with comprehensive financial metrics and additional insights available to subscribers.
Pelareorep is an intravenously delivered oncolytic virus immunotherapy designed to induce anti-cancer immune responses. The company stated that the treatment has shown particular promise in cancers typically unresponsive to immunotherapies.
In other recent news, BeOne Medicines has been the focus of several analyst evaluations and corporate developments. Citizens JMP reiterated its Market Outperform rating for BeOne Medicines, highlighting the company’s robust pipeline and strong cash position, with Brukinsa projected to generate approximately $3.7 billion in revenue for 2025. RBC Capital also maintained an Outperform rating, citing confidence in Brukinsa’s growth potential, with sales expected to reach $6.7 billion by 2034. Leerink Partners echoed this sentiment, reaffirming an Outperform rating and noting the company’s extensive portfolio with over 30 assets in clinical development. Meanwhile, BeOne Medicines completed its corporate re-domiciliation from the Cayman Islands to Switzerland, marking a strategic relocation that included new executive employment agreements and an updated indemnification agreement. Additionally, BeOne Medicines held its Annual Meeting of Shareholders, where key resolutions such as director elections and auditor appointments were approved. The company also secured shareholder approval for mandates to issue and repurchase shares, alongside a Connected Person Placing Authorization for Amgen Inc. These developments reflect BeOne’s ongoing strategic initiatives and robust pipeline advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.